ArticleClinical and molecular hepatology2025

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".

Naoshi NishidaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.